Venous thrombosis and anticoagulant therapy

British Journal of Haematology

Volumn 114, Issue 2, 2001, Pages 258-270

  Mannucci, P M ^a   Poller, L ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dicoumarol; Heparin; Venous thrombosis; Warfarin

Indexed keywords

ACTIVATED PROTEIN C; DICOUMAROL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; SNAKE VENOM; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK FACTOR; VEIN THROMBOSIS;

ANTICOAGULANTS; GREAT BRITAIN; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, MEDIEVAL; HUMANS; INTERNATIONAL NORMALIZED RATIO; PORTRAITS; VENOUS THROMBOSIS;

EID: 0034887532     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02961.x     Document Type: Review

References (102)

1. Familial venous thrombophilia
2. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy
3. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study
4. The historical aspects of venous thrombosis
5. Of uncommon appearances of disease in blood vessels
6. Anticoagulant drugs in the treatment of pulmonary embolism
7. A venographic study of thromboembolism problems
8. A roentgenological and clinical study of the sequels of thrombosis
9. Comparison of the cost of preventing post-operative deep vein thrombosis with either unfractionated or low molecular heparin
10. Prophylaxis against central vein thrombosis
11. Mutation in blood coagulation factor V associated with resistance to activated protein C
12. Preparation of heparin and its use in the first clinical cases
13. Standardisation of the prothrombin time for the control of anticoagulant therapy
14. The 125I fibrinogen uptake test
15. 1methylene-bis-(4 hydroxy-coumarin) which prolongs coagulation and prothrombin time of 120 blood: Preliminary report of experiments and clinical studies. Proceedings of the staff meetings
16. Phlebitis: A study of 748 cases at the Boston City Hospital
17. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent
18. Studies on the hemorrhagic sweet clover disease. I. The preparation of hemorrhagic concentrates
19. Prevention of venous thromboembolism
20. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopaedic and urologic surgery
21. Recurrent venous thromboembolism in patients with a partial deficiency of protein S
22. Nouvelies remarques critiques au sujet du role du foie et de la masse intestinale sur l'action anticoagulante des injections intravasculaires de peptone chez le chien
23. Heparin and postoperative thrombosis
24. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
25. Collective review: A critical evaluation of the problems of thromboembolism (John Calmers Da Costa oration)
26. Les miracles de Saint Louis
27. The chair and venous thrombosis
28. Venous thrombosis. An account of the first documented case
29. Venography, a clinical study
30. Sécrétion d'antithrombine hépatique sans addition de substances étrangères au sang
31. The therapeutic control of anticoagulant therapy
32. Inherited antithrombin deficiency causing thrombophilia
33. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay
34. An affectation of the lymphatic vessels hitherto misunderstood
35. Puerperal thrombophlebitis
36. Two-step warfarin therapy: Prevention of post-operative venous thrombosis without excessive bleeding
37. Prevention of venous thrombembolism
38. Deficiency of protein C in congenital thrombotic disease
39. Anticoagulant protein C pathway defective in majority of thrombophilic patients
40. Problems of acute deep vein thrombosis. The interpretation of signs and symptoms
41. On the action of a secretion obtained from the medicinal leech on the coagulation of the blood
42. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care
43. Oral anticoagulants. Mechanism of action; Clinical effectiveness and therapeutic range
44. The purification of heparin and its presence in blood
45. Two new factors in coagulation, heparin and pro-antithrombin
46. Different intensities of oral anticoagulant treatment of proximal vein thrombosis
47. Diagnostic efficacy of impedance phlethysmography for clinically suspected deep vein thrombosis. A randomized trial
48. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective
49. Observations on the inflammation of the internal coats of veins
50. Antithrombotic therapy for venous thromboembolic disease
51. Prothrombin time standardisation: Report of the expert panel on oral anticoagulant control
52. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement
53. Four heparin prep: Anti-Xa potentiation effect of heparin after subcutaneous injection
54. The chemistry of heparin
55. 125I fibrinogen test
56. The mechanism of inactivation of human factor V and human factor Va by activated protein C
57. Characterization of the molecular defect in factor VRSO6Q
58. Calibration of reference thromboplastin and standardisation of the prothrombin time ratio
59. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
60. 125I-fibrinogen leg scanning: Reassessment of its role for the diagnosis of venous thrombosis in post-operative patients
61. Detection of deep vein thrombosis by real-time B-mode ultrasonography
62. Double blind randomized trial of a very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
63. The discovery of dicumarol and its sequels
64. Questions and answers on prothrombin time standardisation in oral anticoagulant control
65. The thromboplastic action of cephalin
66. Prothrombin time standardisation - 1963 Prothrombin time test survey
67. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment
68. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
69. A double blind randomized placebo control trial of thromboprophylaxis in major elective surgery using once daily injections of a low-molecular weight heparin (Fragmin)
70. The history of the development of oral anticoagulant drugs
71. The standardisation of oral anticoagulant treatment - The Manchester Regional Thromboplastin Scheme
72. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery
73. A comparison of artificially depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration
74. Field studies of coagulometer effects on the ISI of ECAA thromboplastins
75. Multicentre randomized study of computerised anticoagulant dosage
76. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
77. Deep vein thrombosis of the lower limbs: Diagnosis and management
78. The pathology of sweet clover disease in cattle
79. A method to determine the optimal intensity of oral anticoagulant therapy
80. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
81. Beiträge zur kenntnis des peptons und seiner physiologischen bedeutung. Arch für anatomie und physiologie
82. Damaged sweet clover. The cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg
83. Plasma protein S deficiency in familial thrombotic disease
84. Prevention of venous thrombosis and pulmonary embolism in injured patients; a trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur
85. Carcinoma and venous thrombosis: The frequency of associations of carcinoma in the body or tail of the pancreas with multiple venous thrombosis
86. The venographic diagnosis of thrombophlebitis of the lower extremities
87. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis
88. Phlegmasia alba dolens
89. Expert Committee of Biological Standardisation 33rd Report